1r02: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Solution structure of Human Orexin-A:Regulator of Appetite and Wakefulness== | ==Solution structure of Human Orexin-A:Regulator of Appetite and Wakefulness== | ||
<StructureSection load='1r02' size='340' side='right' caption='[[1r02]], [[NMR_Ensembles_of_Models | 1 NMR models]]' scene=''> | <StructureSection load='1r02' size='340' side='right'caption='[[1r02]], [[NMR_Ensembles_of_Models | 1 NMR models]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1r02]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1R02 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1R02 FirstGlance]. <br> | <table><tr><td colspan='2'>[[1r02]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1R02 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1R02 FirstGlance]. <br> | ||
Line 20: | Line 20: | ||
</div> | </div> | ||
<div class="pdbe-citations 1r02" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 1r02" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Orexin and Orexin receptor|Orexin and Orexin receptor]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Hong, E]] | [[Category: Hong, E]] | ||
[[Category: Kim, H Y]] | [[Category: Kim, H Y]] |
Revision as of 08:33, 10 October 2019
Solution structure of Human Orexin-A:Regulator of Appetite and WakefulnessSolution structure of Human Orexin-A:Regulator of Appetite and Wakefulness
Structural highlights
Disease[OREX_HUMAN] Defects in HCRT are the cause of narcolepsy type 1 (NRCLP1) [MIM:161400]. Narcolepsy is a neurological disabling sleep disorder, characterized by excessive daytime sleepiness, sleep fragmentation, symptoms of abnormal rapid-eye-movement (REM) sleep, such as cataplexy, hypnagogic hallucinations, and sleep paralysis. Cataplexy is a sudden loss of muscle tone triggered by emotions, which is the most valuable clinical feature used to diagnose narcolepsy. Human narcolepsy is primarily a sporadically occurring disorder but familial clustering has been observed. Note=Human narcolepsy is associated with a deficient orexin system. Orexins are absent and/or greatly diminished in the brain and cerebrospinal fluid (CSF) of most narcoleptic patients.[1] Function[OREX_HUMAN] Neuropeptides that play a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested. Orexin-A binds to both OX1R and OX2R with a high affinity, whereas orexin-B binds only to OX2R with a similar high affinity. Publication Abstract from PubMedOrexin-A and orexin-B (hypocretin-1 and hypocretin-2, respectively) are important hypothalamic neuro-peptides, which are encoded by a single mRNA transcript and stimulate food intake as well as regulate wakefulness. Here we determined the solution structure of orexin-A by NMR spectroscopy and by simulated-annealing calculation. The structural features of orexin-A involve two alpha-helices, with the hydrophobic residues disposed to on one side of helix, and hydrophilic residues to the other. A hydrophilic turn induced by two disulfide bonds provides the key difference between orexin-A and -B. With previous mutagenic studies, the derived structure of orexin-A provides us with a structure-functional view for novel drug design. Solution structure of human orexin-A: regulator of appetite and wakefulness.,Kim HY, Hong E, Kim JI, Lee W J Biochem Mol Biol. 2004 Sep 30;37(5):565-73. PMID:15479620[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|